TNFRSF8 TNF receptor superfamily member 8
ENSG00000120949 · protein coding · Open Targets profile
Receptor for TNFSF8/CD30L (PubMed:8391931). May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa- B (PubMed:8999898). {ECO:0000269|PubMed:8391931, ECO:0000269|PubMed:8999898}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Antibody
- Advanced Clinical, UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM, Human Protein Atlas loc
- PROTAC
- Database Ubiquitination, Half-life Data
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.3674199879169464 (upper bound 0.5098199844360352). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 97 registry trials, updated in the last three years, of the most advanced drugs against TNFRSF8 (brentuximab vedotin, SGN-30, iratumumab), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Alex F HerreraCity of Hope Medical Center · 4 of 5 trials Phase 2+
- Alex HerreraCity of Hope Medical Center · 2 of 2 trials Phase 2+
- Peter BorchmannUniversity Hospital of Cologne · 2 of 2 trials Phase 2+
- Vaishalee P KenkreECOG-ACRIN Cancer Research Group · 2 of 2 trials Phase 2+
- Mitchell CairoNew York Medical College · 1 of 2 trials Phase 2+
- Ajay GopalFred Hutch/University of Washington Cancer Consortium · 1 of 1 trials Phase 2+
- Ajay K. GopalFred Hutch/University of Washington Cancer Consortium · 1 of 1 trials Phase 2+
- Alison MoskowitzMemorial Sloan Kettering Cancer Center · 1 of 1 trials Phase 2+
- Allison MoskowitzMemorial Sloan Kettering Cancer Center · 1 of 1 trials Phase 2+
- Anna SuredaInstitut Català d'Oncologia, Hospital Duran i Reynals · 1 of 1 trials Phase 2+
- Anne S TsaoM.D. Anderson Cancer Center · 1 of 1 trials Phase 2+
- Auris O HuenM.D. Anderson Cancer Center · 1 of 1 trials Phase 2+
- Bouthaina DabajaM.D. Anderson Cancer Center · 1 of 1 trials Phase 2+
- Bruce D ChesonAcademic and Community Cancer Research United · 1 of 1 trials Phase 2+
- Catherine S DiefenbachECOG-ACRIN Cancer Research Group · 1 of 1 trials Phase 2+
Registry trials of brentuximab vedotin, SGN-30, iratumumab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 67 of 89 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 8 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
38 trials of drugs against TNFRSF8 were stopped early; 5 give no reason
Terminated, withdrawn and suspended interventional trials of brentuximab vedotin, SGN-30, iratumumab, HEFI-1, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 38.
- suspended · 2026-06-15 · University of Alabama at Birmingham · Brentuximab vedotin“IRB audit”
- terminated · 2025-08-28 · Seagen Inc. · brentuximab vedotin“The study was prematurely discontinued as the sponsor believes the data collected is enough to show the safety and efficacy of the combinations studied in all cohorts. The decision was not based on any safety and/or efficacy concerns.”
- suspended · 2025-03-30 · Insel Gruppe AG, University Hospital Bern · Brentuximab Vedotin“low accrual”
- terminated · 2025-02-10 · Seagen Inc. · brentuximab vedotin“Study closed due to portfolio prioritization”
- withdrawn · 2024-03-20 · National Cancer Institute (NCI) · Brentuximab Vedotin“Other - Protocol moved to Withdrawn”
- terminated · 2024-01-10 · Bristol-Myers Squibb · Brentuximab vedotin“Insufficient enrollment.”
- terminated · 2023-10-13 · Seagen Inc. · brentuximab vedotin“Study stopped early due to low patient accrual.”
- withdrawn · 2023-10-10 · Northwestern University · Brentuximab Vedotin“Study inactivated due to zero accruals”
- terminated · 2023-10-10 · M.D. Anderson Cancer Center · Brentuximab Vedotin“Slow accrual.”
- withdrawn · 2023-02-14 · Seagen Inc. · brentuximab vedotin“Study withdrawn due to low patient accrual.”
- withdrawn · 2023-02-03 · University of Kansas Medical Center · Brentuximab Vedotin“accrual not met”
- withdrawn · 2022-06-23 · Yale University · Brentuximab Vedotin“Lack of funding”
- terminated · 2022-03-03 · Arbeitsgemeinschaft medikamentoese Tumortherapie · Brentuximab vedotin“Due to slow recruitment, recruitment of new patients was stopped, FU was completed for enrolled patients”
- terminated · 2021-09-01 · Northwestern University · brentuximab vedotin“Lack of funding”
- terminated · 2021-05-27 · Fondazione Italiana Linfomi - ETS · Brentuximab Vedotin“expected accrual not reached”
- terminated · 2020-12-10 · Masonic Cancer Center, University of Minnesota · Brentuximab Vedotin“Funding Unavailable”
- terminated · 2019-12-12 · Mayo Clinic · Brentuximab Vedotin“funding withdrawal”
- terminated · 2019-12-10 · Nabil Adra · Brentuximab Vedotin“lack of funding/ benefit”
- terminated · 2019-11-27 · M.D. Anderson Cancer Center · Brentuximab Vedotin“Slow Accrual”
- withdrawn · 2019-10-10 · University of Washington · Brentuximab Vedotin“Administrative closure”
- withdrawn · 2019-04-30 · City of Hope Medical Center · Brentuximab Vedotin“contract not executed”
- terminated · 2018-10-17 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Brentuximab vedotin“Low accrual”
- terminated · 2018-10-16 · Seagen Inc. · Brentuximab Vedotin“Sponsor decision based on portfolio prioritization”
- withdrawn · 2018-07-27 · Eric Bernicker, MD · Brentuximab Vedotin“lack of funding”
- terminated · 2018-07-26 · Massachusetts General Hospital · Brentuximab Vedotin“Toxicity”
Paediatric incentives and obligations for TNFRSF8's drugs
For brentuximab vedotin, SGN-30, iratumumab, HEFI-1: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: yes · TNFRSF8 is on the list. Membership alone neither requires nor waives a pediatric study.Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-000980-PIP01-10-M07 (Brentuximab vedotin, Treatment of anaplastic large cell lymphoma;Treatment of Hodgkin lymphoma): PM: decision on the application for modification of an agreed PIP, 28 Jan 2021; compliance positive 25 Jun 2021; EMEA-000980-PIP04-18 (Brentuximab vedotin, Treatment of Mature T and NK neoplasms (excluding anaplastic large-cell lymphoma and cutaneous Tcell lymphoma)): W: decision granting a waiver in all age groups for all conditions or indications, 8 Oct 2018; EMEA-000980-PIP02-15 (Brentuximab vedotin, Treatment of Cutaneous T-Cell Lymphoma): W: decision granting a waiver in all age groups for all conditions or indications, 7 Aug 2015Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/11/939 withdrawn 11 Jan 2012: Treatment of cutaneous T-cell lymphoma; EU/3/08/596 withdrawn 15 Jan 2009: Treatment of Hodgkin's lymphomaRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Adcetris: authorised since 25 Oct 2012Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA EPAR Adcetris, 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: yes · Brentuximab vedotin [Adcetris], 10 Nov 2022: Treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamideRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 49 interventional studies of brentuximab vedotin, sgn-30, iratumumab, hefi-1 include patients under 18; 19 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 4 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.